
    
      Phase 1: To determine the maximum tolerated daily dose (MTDD) of KW 2449 when administered to
      subjects with AML who are not candidates for approved therapy.

      This was originally a Phase 1/Phase 2 study. However, a tolerable dose that had the potential
      for efficacy could not be identified in Phase 1. Therefore, Phase 2 was never conducted.
    
  